



(51) International Patent Classification:

C07K 16/28 (2006.01) C12N 15/10 (2006.01)
C07K 16/00 (2006.01) C40B 40/02 (2006.01)
C40B 40/08 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2023/064624

(22) International Filing Date:

31 May 2023 (31.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2208027.9 31 May 2022 (31.05.2022) GB
2214718.5 06 October 2022 (06.10.2022) GB

(71) Applicant: ONCOPEPTIDES INNOVATION 1 AB
[SE/SE]; Luntmakargatan 46, 111 37 Stockholm (SE).(72) Inventors: NYGREN, Per-Åke; c/o Kungliga Tekniska
Högskolan, Brinellvägen 8, SE-100 44 Stockholm (SE).
GIANG, Kim Anh; c/o Kungliga Tekniska Högskolan,
Brinellvägen 8, SE-100 44 Stockholm (SE). NILVE-
BRANT, Johan; c/o Kungliga Tekniska Högskolan, Brinell-
vägen 8, SE-100 44 Stockholm (SE). LEHMANN,
Fredrik; c/o Oncopeptides Innovation 1 AB, Luntmakar-

gatan 46, 111 37 Stockholm (SE). GELIUS, Stefan Svens-
son; c/o Oncopeptides Innovation 1 AB, Luntmakargatan
46, 111 37 Stockholm (SE).

(74) Agent: ABEL & IMRAY LLP; Westpoint Building, James
Street West, Bath Bath and North East Somerset BA1 2DA
(GB).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: NOVEL POLYPEPTIDES

Figure 1a





Figure 1b



(57) Abstract: The invention provides a CD16a-binding polypeptide which comprises at least one motif that binds to CD16a, wherein said polypeptide comprises the following structure: [N-terminal portion]-[Helix 1]-[Separating portion]-[Helix 2]-[C-terminal portion] the CD16a-binding motif being the portion [Helix 1]-[Separating portion]- [Helix 2]. The invention further provides pharmaceutical compositions comprising the CD16a- binding polypeptide, and the use of the CD16a-binding polypeptide or pharmaceutical compositions as a medicament, particularly for use in the treatment or prophylaxis of cancers such as multiple myeloma.

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*